Voyager Therapeutics (NASDAQ:VYGR) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note published on Friday morning, Marketbeat reports. The firm issued an overweight rating and a $5.73 target price on the stock.

A number of other brokerages have also commented on VYGR. Leerink Partners started coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Wedbush began coverage on Voyager Therapeutics in a report on Friday, November 29th. They set an “outperform” rating and a $11.00 price target for the company. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Voyager Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $15.97.

Voyager Therapeutics Trading Down 4.9 %

Shares of NASDAQ VYGR opened at $5.45 on Friday. The company has a market capitalization of $297.71 million, a P/E ratio of 7.68 and a beta of 0.93. Voyager Therapeutics has a 12 month low of $5.19 and a 12 month high of $10.66. The stock has a 50 day moving average of $6.09 and a 200-day moving average of $6.81.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the previous year, the business posted ($0.59) earnings per share. Analysts predict that Voyager Therapeutics will post -0.89 EPS for the current fiscal year.

Insider Activity

In related news, COO Robin Swartz sold 6,500 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in VYGR. Great Point Partners LLC acquired a new stake in shares of Voyager Therapeutics in the 2nd quarter valued at $12,668,000. Erste Asset Management GmbH acquired a new stake in Voyager Therapeutics in the third quarter valued at about $6,192,000. Armistice Capital LLC grew its position in Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after acquiring an additional 528,000 shares during the last quarter. American Century Companies Inc. raised its stake in Voyager Therapeutics by 32.4% during the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock worth $8,063,000 after acquiring an additional 249,659 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Voyager Therapeutics by 17.7% in the second quarter. Bank of New York Mellon Corp now owns 294,420 shares of the company’s stock worth $2,329,000 after acquiring an additional 44,289 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.